A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Non-hematologic Malignancy

Interventions

DRUG

Sapanisertib

Sapanisertib capsules

DRUG

Paclitaxel

Paclitaxel injection

Trial Locations (5)

Scottsdale

Sarasota

Oklahoma City

Germantown

Nashville